Hiroomi Tada
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research 3
- CAR-T cell therapy research 3
- Colorectal Cancer Treatments and Studies 2
- Hepatology top 10%
-
- Lung Cancer Treatments and Mutations 3
-
- PI3K/AKT/mTOR signaling in cancer 2
-
- Virus-based gene therapy research 2
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 2
-
- Neuroendocrine Tumor Research Advances 2
- Co-authors
- Nikki LevinStephen BradyJon R. WardBruce E. JohnsonJie WangYan SunPeter LangmuirShukui Qin
- Journals
- Journal of Clinical Investigation (1 paper)Journal of Clinical Oncology (2 papers)Blood (1 paper)
- Partner nations
- United StatesNetherlandsUnited Kingdom
In The Last Decade
Hiroomi Tada
13 papers receiving 936 citations
Peers
Comparison fields: 5 of 67
- Oncology 537
- Hepatology 104
- Pulmonary and Respiratory Medicine 397
- Cancer Research 146
- Molecular Biology 365
Countries citing papers authored by Hiroomi Tada
This map shows the geographic impact of Hiroomi Tada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroomi Tada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroomi Tada more than expected).
Fields of papers citing papers by Hiroomi Tada
This network shows the impact of papers produced by Hiroomi Tada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroomi Tada. The network helps show where Hiroomi Tada may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hiroomi Tada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 6 | |
| 2 | 2019 | 30 | |
| 3 | 2018 | 1 | |
| 4 | 2015 | 70 | |
| 5 | 2015 | 2 | |
| 6 | 2013 | 90 | |
| 7 | 2010 | 339 | |
| 8 | 2006 | 140 | |
| 9 | 2005 | 139 | |
| 10 | 2004 | 1 | |
| 11 | 2001 | 17 | |
| 12 | 2001 | 43 | |
| 13 | 1987 | 73 |
About Hiroomi Tada
Hiroomi Tada is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine, having authored 13 papers that have together received 951 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (3 papers), CAR-T cell therapy research (3 papers), Lung Cancer Treatments and Mutations (3 papers), Virus-based gene therapy research (2 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Neuroendocrine Tumor Research Advances (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Oncology (537 citations), Hepatology (104 citations) and Pulmonary and Respiratory Medicine (397 citations). Hiroomi Tada has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Nikki Levin, Stephen Brady, Jon R. Ward, Bruce E. Johnson, Jie Wang, Yan Sun, Peter Langmuir, Shukui Qin, Nagahiro Saijo and Caicun Zhou. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.